MeSH term
Frequency | Condition_Probility | Humans | 732 | 0.0 |
Base Sequence | 49 | 0.0 |
Blotting, Northern | 5 | 0.0 |
Cell Line | 38 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA Mutational Analysis | 11 | 0.0 |
Family Health | 5 | 0.0 |
*Frameshift Mutation | 2 | 1.0 |
Male | 332 | 0.0 |
Polymerase Chain Reaction | 27 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Pyruvate Carboxylase/*genetics/metabolism | 2 | 100.0 |
Pyruvate Carboxylase Deficiency Disease/enzymology/*genetics | 2 | 100.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 372 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Blotting, Western | 11 | 0.0 |
Case-Control Studies | 28 | 0.0 |
Female | 329 | 0.0 |
Middle Aged | 219 | 0.0 |
Protein C/*physiology | 10 | 18.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Thrombin/biosynthesis | 2 | 5.0 |
Amino Acid Sequence | 60 | 0.0 |
Animals | 152 | 0.0 |
Mice | 43 | 0.0 |
Models, Molecular | 15 | 0.0 |
Molecular Sequence Data | 79 | 0.0 |
Peptides/chemistry | 3 | 0.0 |
*Proprotein Convertase 1 | 3 | 20.0 |
Proprotein Convertases | 9 | 19.0 |
Protein Folding | 2 | 0.0 |
Protein Structure, Tertiary | 10 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 31 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 157 | 0.0 |
Sequence Homology, Amino Acid | 15 | 0.0 |
Solutions | 3 | 1.0 |
Bile Acids and Salts/pharmacology | 2 | 14.0 |
Cholesterol/*pharmacology | 2 | 10.0 |
Micelles | 3 | 6.0 |
Phosphatidylcholines/*metabolism | 23 | 46.0 |
Sphingomyelins/*metabolism | 2 | 28.0 |
Adult | 244 | 0.0 |
Chromatography, Gas | 3 | 3.0 |
Chronic Disease | 4 | 0.0 |
Disease Models, Animal | 5 | 0.0 |
Guinea Pigs | 6 | 0.0 |
Infant | 29 | 0.0 |
Infant, Newborn | 26 | 0.0 |
Pregnancy | 42 | 0.0 |
Immunoassay/*methods | 2 | 2.0 |
Milk/chemistry | 2 | 13.0 |
Protein C/*analysis | 37 | 64.0 |
Swine | 3 | 0.0 |
Buffers | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 17 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 16 | 0.0 |
Protein C/*isolation & purification | 4 | 100.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
*Blood Coagulation Factors | 6 | 20.0 |
Cells, Cultured | 44 | 0.0 |
Endothelium, Vascular/cytology/*metabolism | 2 | 1.0 |
Enzyme Activation | 26 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Phosphorylation | 5 | 0.0 |
Protein C/*metabolism | 26 | 17.0 |
Receptor, PAR-1 | 2 | 9.0 |
Receptors, Cell Surface/metabolism | 4 | 0.0 |
Signal Transduction | 10 | 0.0 |
Thrombin/metabolism | 10 | 6.0 |
DNA Primers | 11 | 0.0 |
Lung/cytology/*metabolism | 2 | 6.0 |
Mice, Transgenic | 2 | 0.0 |
Rats | 46 | 0.0 |
Administration, Oral | 6 | 0.0 |
Biological Markers/blood | 14 | 1.0 |
Child | 55 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 2 | 1.0 |
Reproducibility of Results | 10 | 0.0 |
Sensitivity and Specificity | 17 | 0.0 |
Aged | 131 | 0.0 |
English Abstract | 63 | 0.0 |
Hyperparathyroidism/etiology | 2 | 20.0 |
Retrospective Studies | 17 | 0.0 |
Aged, 80 and over | 43 | 0.0 |
Antithrombin III/*analysis | 13 | 15.0 |
Longitudinal Studies | 4 | 0.0 |
Predictive Value of Tests | 8 | 0.0 |
Prospective Studies | 22 | 0.0 |
Protein S/*analysis | 9 | 69.0 |
Recurrence | 7 | 0.0 |
Risk Factors | 34 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Hemorrhage/etiology | 2 | 9.0 |
*Hemostasis | 7 | 5.0 |
Ploidies | 3 | 1.0 |
Acute Disease | 10 | 0.0 |
Exercise/*physiology | 2 | 0.0 |
Time Factors | 28 | 0.0 |
Adolescent | 88 | 0.0 |
Blood Coagulation Tests | 22 | 11.0 |
Blood Proteins/*metabolism | 4 | 2.0 |
Fibrin Fibrinogen Degradation Products/metabolism | 8 | 9.0 |
Plasminogen/metabolism | 5 | 12.0 |
Plasminogen Activator Inhibitor 1/metabolism | 3 | 6.0 |
Protein S/metabolism | 5 | 14.0 |
Remission Induction | 3 | 0.0 |
Survival Analysis | 5 | 0.0 |
Thrombomodulin/metabolism | 4 | 13.0 |
Antibodies, Monoclonal/immunology | 9 | 0.0 |
Equipment Design | 3 | 2.0 |
Evaluation Studies | 6 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Fiber Optics | 2 | 15.0 |
Models, Chemical | 3 | 0.0 |
Protein C/*analysis/immunology/standards | 2 | 100.0 |
Protein C Deficiency/blood/*diagnosis | 2 | 100.0 |
Blood Coagulation Factors/analysis | 7 | 11.0 |
Comparative Study | 115 | 0.0 |
Detergents/pharmacology | 2 | 1.0 |
Fibrinolysis | 8 | 5.0 |
Antithrombins/metabolism | 3 | 18.0 |
Blood Coagulation/drug effects | 7 | 6.0 |
Fibrinogen/metabolism | 4 | 1.0 |
Platelet Count | 9 | 1.0 |
Protein C/metabolism | 17 | 19.0 |
Treatment Outcome | 14 | 0.0 |
Protein Processing, Post-Translational | 7 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 3 | 1.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
Golgi Apparatus/metabolism | 3 | 1.0 |
Apolipoprotein A-I/*metabolism | 2 | 4.0 |
Biological Transport | 9 | 0.0 |
Cell Membrane/metabolism | 6 | 0.0 |
Choline/metabolism | 7 | 18.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Dose-Response Relationship, Drug | 14 | 0.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Kinetics | 42 | 0.0 |
Lipids/*metabolism | 4 | 1.0 |
Phospholipids/metabolism | 11 | 5.0 |
Protein Binding | 13 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Up-Regulation | 3 | 0.0 |
Factor V/genetics | 5 | 5.0 |
Protein S Deficiency/complications | 2 | 22.0 |
Blood Coagulation | 8 | 4.0 |
Plasminogen Activator Inhibitor 1/blood | 3 | 2.0 |
Tissue Plasminogen Activator/blood | 4 | 3.0 |
Chromatography, High Pressure Liquid | 12 | 0.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Transfection | 23 | 0.0 |
Binding Sites | 29 | 0.0 |
Cell Adhesion | 3 | 0.0 |
Cell Movement | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Microscopy, Confocal | 5 | 0.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Tumor Cells, Cultured | 21 | 0.0 |
*Alleles | 4 | 0.0 |
Cohort Studies | 7 | 0.0 |
Factor V/*genetics | 9 | 5.0 |
Genetic Predisposition to Disease | 11 | 0.0 |
Genotype | 14 | 0.0 |
Mutation | 18 | 0.0 |
Prothrombin/*genetics | 2 | 3.0 |
Diagnostic Errors | 3 | 4.0 |
Factor V/analysis | 4 | 26.0 |
Protein S/analysis | 10 | 29.0 |
Reagent Kits, Diagnostic/*standards | 3 | 13.0 |
Thrombosis/blood | 2 | 10.0 |
CHO Cells | 7 | 0.0 |
Culture Media, Conditioned | 3 | 0.0 |
Hamsters | 12 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 7 | 1.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Temperature | 3 | 0.0 |
*Ischemic Preconditioning, Myocardial | 2 | 66.0 |
Models, Biological | 8 | 0.0 |
Phenotype | 20 | 0.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Monocytes/*metabolism | 3 | 0.0 |
False Positive Reactions | 2 | 0.0 |
Protein C/*analysis/metabolism | 2 | 66.0 |
Thromboembolism/blood | 2 | 25.0 |
Thrombophilia/blood/diagnosis | 2 | 40.0 |
Alleles | 13 | 0.0 |
Odds Ratio | 4 | 0.0 |
Thrombosis/*genetics | 4 | 21.0 |
Italy | 2 | 0.0 |
Molecular Weight | 13 | 0.0 |
*Point Mutation | 7 | 0.0 |
Protein C Deficiency/*genetics | 6 | 60.0 |
Protein Precursors/*metabolism | 2 | 2.0 |
*Protein Processing, Post-Translational | 3 | 1.0 |
Sequence Analysis | 3 | 0.0 |
Substrate Specificity | 11 | 0.0 |
Calcium/pharmacology | 7 | 3.0 |
Hydrogen-Ion Concentration | 5 | 0.0 |
Ligands | 2 | 0.0 |
Phosphorylcholine/*metabolism | 5 | 45.0 |
Child, Preschool | 40 | 0.0 |
Fibrinolytic Agents/metabolism | 2 | 16.0 |
Partial Thromboplastin Time | 19 | 9.0 |
Venous Thrombosis/*blood | 2 | 16.0 |
Dogs | 2 | 0.0 |
Antibodies, Bacterial/immunology | 2 | 4.0 |
Cross Reactions | 7 | 0.0 |
Lipoproteins, LDL/*immunology | 3 | 23.0 |
Phosphorylcholine/*immunology | 5 | 83.0 |
Cell Nucleus/metabolism | 5 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Immunohistochemistry | 17 | 0.0 |
Protein Isoforms | 2 | 0.0 |
Pulmonary Surfactants/*metabolism | 2 | 28.0 |
Recombinant Fusion Proteins/metabolism | 3 | 0.0 |
Risk | 11 | 1.0 |
HLA-DQ Antigens/*genetics | 3 | 0.0 |
Haplotypes | 6 | 0.0 |
Mechanoreceptors/physiology | 2 | 22.0 |
Skin/innervation | 2 | 11.0 |
Surface Properties | 4 | 2.0 |
Touch/*physiology | 3 | 33.0 |
Electrocardiography | 2 | 0.0 |
*Hemodynamic Processes | 2 | 4.0 |
Incidence | 13 | 1.0 |
Intensive Care Units, Pediatric | 2 | 40.0 |
Prognosis | 13 | 0.0 |
Proprotein Convertase 2 | 3 | 15.0 |
Subtilisins/*metabolism | 3 | 27.0 |
Cloning, Molecular | 9 | 0.0 |
DNA, Complementary | 6 | 0.0 |
Blotting, Western/methods | 2 | 1.0 |
Citrates/pharmacology | 2 | 11.0 |
RNA, Messenger/analysis | 3 | 0.0 |
3T3 Cells | 3 | 0.0 |
*Chromosomes, Human, Pair 11 | 2 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
Repressor Proteins/genetics/*metabolism | 2 | 1.0 |
*Transcription Factors | 2 | 0.0 |
Evolution | 2 | 0.0 |
Mammals | 4 | 1.0 |
Sequence Alignment | 6 | 0.0 |
Gene Deletion | 2 | 0.0 |
Protein C/*genetics/*metabolism | 2 | 50.0 |
Carboplatin/administration & dosage/adverse effects | 3 | 27.0 |
Cisplatin/administration & dosage/adverse effects | 2 | 8.0 |
Paclitaxel/administration & dosage/adverse effects | 3 | 50.0 |
Quality of Life | 2 | 1.0 |
Regression Analysis | 4 | 0.0 |
Survival Rate | 10 | 0.0 |
United States/epidemiology | 2 | 0.0 |
Fatal Outcome | 3 | 0.0 |
Precipitation | 4 | 2.0 |
Analysis of Variance | 8 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Amine Oxidoreductases/genetics | 2 | 1.0 |
Homocysteine/blood | 2 | 1.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 0.0 |
Prevalence | 8 | 0.0 |
Taiwan/epidemiology | 5 | 4.0 |
Cholesterol/metabolism | 3 | 1.0 |
Hemolysis | 2 | 0.0 |
L-Lactate Dehydrogenase/metabolism | 2 | 1.0 |
Phosphatidylcholines/*metabolism/pharmacology | 2 | 100.0 |
Tissue Distribution | 4 | 0.0 |
Brain/*metabolism | 2 | 0.0 |
*Magnetic Resonance Spectroscopy | 2 | 4.0 |
Phospholipids/*metabolism | 17 | 14.0 |
Phosphorus/diagnostic use | 2 | 66.0 |
*Blood Coagulation | 14 | 6.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Thrombomodulin/*metabolism | 9 | 37.0 |
Thromboplastin/metabolism | 5 | 6.0 |
*Chromosome Mapping | 2 | 0.0 |
Gene Frequency | 12 | 0.0 |
HLA Antigens/*genetics | 2 | 0.0 |
*Haplotypes | 4 | 1.0 |
Linkage (Genetics) | 2 | 0.0 |
Reference Values | 30 | 0.0 |
Spain | 3 | 0.0 |
*Fibrinolysis | 9 | 6.0 |
Venous Thrombosis/etiology | 3 | 27.0 |
Arachidonic Acid/metabolism | 5 | 5.0 |
Fatty Acids/*metabolism | 3 | 3.0 |
Phosphatidylcholines/metabolism | 13 | 14.0 |
Anticoagulants/therapeutic use | 5 | 7.0 |
Abortion, Habitual/*blood | 2 | 33.0 |
Antithrombin III/analysis | 20 | 10.0 |
Pregnancy Outcome | 2 | 0.0 |
Protein C/analysis | 17 | 30.0 |
Cell Division/drug effects | 3 | 0.0 |
Drug Synergism | 5 | 0.0 |
Age Factors | 11 | 0.0 |
Neoplasm Staging | 6 | 0.0 |
Endothelins/*blood/*genetics | 2 | 100.0 |
Models, Genetic | 2 | 0.0 |
Protein C/biosynthesis | 2 | 50.0 |
Protein C/*genetics | 11 | 24.0 |
Protein S/*genetics | 2 | 11.0 |
*Antithrombin III Deficiency | 6 | 37.0 |
Factor X/analysis | 2 | 40.0 |
Prothrombin/analysis | 5 | 6.0 |
Down-Regulation | 4 | 0.0 |
Tritium | 3 | 1.0 |
Endocytosis | 3 | 0.0 |
Endosomes/metabolism | 2 | 1.0 |
Point Mutation | 10 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Prostatic Neoplasms/*pathology | 2 | 1.0 |
Species Specificity | 7 | 0.0 |
Mutagenesis, Site-Directed | 19 | 0.0 |
Anticoagulants/blood | 2 | 11.0 |
Blood Coagulation Factors/metabolism | 5 | 9.0 |
Anticoagulants/metabolism | 5 | 29.0 |
Enzyme Activation/drug effects | 10 | 1.0 |
Glycosylation | 4 | 0.0 |
Neoplasm Proteins/metabolism | 3 | 0.0 |
Protein C/*chemistry/metabolism | 2 | 33.0 |
Protein Conformation | 23 | 0.0 |
*Fibrinolytic Agents | 2 | 28.0 |
Brain/metabolism | 2 | 0.0 |
Docosahexaenoic Acids/blood | 3 | 33.0 |
Fatty Acids/*blood | 5 | 17.0 |
Lysophosphatidylcholines/blood | 3 | 37.0 |
Phosphatidylcholines/blood | 7 | 31.0 |
Phosphatidylethanolamines/blood | 6 | 60.0 |
Furin | 5 | 11.0 |
Mutation, Missense | 2 | 0.0 |
Follow-Up Studies | 10 | 0.0 |
Transplantation, Homologous | 2 | 0.0 |
Carrier Proteins/genetics | 3 | 0.0 |
Chromosome Mapping | 7 | 0.0 |
Chromosomes, Human, Pair 11/*genetics | 2 | 0.0 |
*Membrane Proteins | 3 | 0.0 |
Pyruvate Carboxylase/genetics | 4 | 100.0 |
*Apoptosis | 2 | 0.0 |
*Silanes | 2 | 50.0 |
Antibodies, Anticardiolipin/blood | 3 | 11.0 |
Factor V | 3 | 21.0 |
Prothrombin/genetics | 2 | 3.0 |
*Renal Veins | 2 | 100.0 |
Cell Line, Tumor | 3 | 0.0 |
*Mutation | 5 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
In Vitro | 22 | 0.0 |
Neisseria meningitidis | 2 | 28.0 |
Binding, Competitive | 8 | 0.0 |
Factor Va/*metabolism | 2 | 8.0 |
Platelet Activation | 2 | 1.0 |
Prothrombin/metabolism | 4 | 5.0 |
Anticoagulants/*pharmacology | 2 | 2.0 |
Fibrinolysis/*drug effects | 3 | 4.0 |
Rabbits | 12 | 0.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Ifosfamide/administration & dosage/adverse effects | 2 | 33.0 |
Ovarian Neoplasms/*drug therapy/pathology/surgery | 2 | 66.0 |
Biological Markers | 3 | 0.0 |
Statistics, Nonparametric | 5 | 0.0 |
Insulin/blood | 2 | 0.0 |
Antithrombin III/metabolism | 10 | 8.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Logistic Models | 3 | 0.0 |
Plasminogen/deficiency | 2 | 50.0 |
Lipids/metabolism | 3 | 0.0 |
Cholesterol/*metabolism | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Fluorescence Polarization | 3 | 5.0 |
Lipoproteins, HDL/*metabolism | 3 | 2.0 |
*Lipid Peroxidation | 2 | 4.0 |
Lipoproteins, LDL/metabolism | 5 | 2.0 |
Lipoproteins, VLDL/metabolism | 3 | 2.0 |
Syndrome | 4 | 0.0 |
Carbon Radioisotopes | 2 | 2.0 |
Lysophosphatidylcholines/*metabolism | 2 | 40.0 |
Oxidation-Reduction | 10 | 0.0 |
Thrombin/pharmacology | 4 | 1.0 |
Nuclear Magnetic Resonance, Biomolecular | 2 | 1.0 |
Phosphatidylcholines/*chemistry | 3 | 100.0 |
Phosphatidylcholines/*pharmacology | 3 | 27.0 |
Blood Coagulation Disorders/blood/*etiology | 2 | 40.0 |
Japan | 4 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
*Polymorphism, Genetic | 7 | 0.0 |
Anticoagulants/*therapeutic use | 2 | 4.0 |
Intensive Care Units | 2 | 3.0 |
Protein C/*therapeutic use | 2 | 28.0 |
Biopsy | 4 | 0.0 |
Estradiol/blood | 2 | 0.0 |
Hydrocortisone/blood | 2 | 0.0 |
Immunoassay | 3 | 1.0 |
Prostate-Specific Antigen/blood | 2 | 2.0 |
*Renal Dialysis | 7 | 1.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
Phosphatidylcholines/*biosynthesis | 12 | 92.0 |
Rats, Wistar | 6 | 0.0 |
*Models, Molecular | 2 | 1.0 |
Structure-Activity Relationship | 17 | 0.0 |
Blood Coagulation/*drug effects | 5 | 4.0 |
Cattle | 13 | 0.0 |
Fibrinolytic Agents/*pharmacology | 2 | 6.0 |
Horses | 2 | 1.0 |
Indoles/*pharmacology | 4 | 4.0 |
Photosensitizing Agents/*pharmacology | 2 | 13.0 |
Vesicular stomatitis-Indiana virus/*drug effects | 2 | 33.0 |
Fibrin Fibrinogen Degradation Products/analysis | 4 | 3.0 |
Hemostasis | 4 | 3.0 |
Lipoproteins/*blood | 6 | 1.0 |
Peptide Hydrolases/analysis | 6 | 4.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Protein Precursors/genetics/*metabolism | 2 | 6.0 |
Blood Coagulation Factors/*analysis | 5 | 6.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Protein C Inhibitor/metabolism | 2 | 66.0 |
Blood Coagulation/*immunology | 3 | 33.0 |
Complement 4b/metabolism | 2 | 8.0 |
*Complement Inactivators | 6 | 7.0 |
*Glycoproteins | 5 | 0.0 |
Protein Biosynthesis | 2 | 0.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Risk Assessment | 2 | 0.0 |
Tetrazolium Salts | 2 | 3.0 |
Thiazoles | 2 | 3.0 |
Thymidine/metabolism | 3 | 0.0 |
Anti-Inflammatory Agents/*pharmacology | 2 | 2.0 |
Sheep | 2 | 0.0 |
Cell Division | 7 | 0.0 |
Flow Cytometry/methods | 2 | 0.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 3 | 2.0 |
Phosphatidylglycerols/*analysis | 2 | 100.0 |
Gene Expression | 6 | 0.0 |
Proprotein Convertase 5 | 2 | 28.0 |
Carbon Isotopes | 2 | 3.0 |
Deuterium | 2 | 7.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Phosphatidylethanolamines/metabolism | 7 | 35.0 |
Antigens/blood | 7 | 13.0 |
Heparin/therapeutic use | 7 | 16.0 |
Mutation/genetics | 2 | 0.0 |
Receptors, Complement/metabolism | 3 | 5.0 |
Antibodies, Monoclonal | 14 | 0.0 |
Biotin | 2 | 3.0 |
Protein C Deficiency/diagnosis | 3 | 75.0 |
Calcium/*metabolism | 2 | 0.0 |
Antithrombins/deficiency | 3 | 75.0 |
*Blood Coagulation Tests | 5 | 21.0 |
Lupus Coagulation Inhibitor/pharmacology | 3 | 60.0 |
Protein C Deficiency/blood/genetics | 2 | 66.0 |
Protein S Deficiency/blood/genetics | 2 | 50.0 |
*Prothrombin Time | 3 | 15.0 |
Immunoenzyme Techniques | 5 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Subtilisins/*biosynthesis/genetics | 2 | 100.0 |
*Androgen-Binding Protein | 2 | 50.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Phospholipid Transfer Proteins | 3 | 15.0 |
*Arginine | 2 | 7.0 |
Drug Resistance | 4 | 0.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Prothrombin/*metabolism | 2 | 6.0 |
Heparin/*pharmacology | 2 | 1.0 |
Lysine | 2 | 4.0 |
Cell Compartmentation | 2 | 0.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
*Crotalid Venoms | 2 | 66.0 |
Factor VIII/analysis | 2 | 1.0 |
Mass Screening | 2 | 1.0 |
*Peptides | 2 | 3.0 |
DNA Primers/genetics | 2 | 0.0 |
HL-60 Cells | 3 | 0.0 |
Pedigree | 23 | 0.0 |
Protein C/genetics | 8 | 53.0 |
Antithrombin III/*metabolism | 11 | 17.0 |
Fibrinogen/*metabolism | 3 | 4.0 |
Protein S/*metabolism | 6 | 27.0 |
1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 12.0 |
Diglycerides/metabolism | 3 | 6.0 |
Isoflurophate/pharmacology | 2 | 8.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*metabolism | 2 | 3.0 |
Statistics | 2 | 0.0 |
Thrombosis/*etiology | 6 | 12.0 |
Mexico | 5 | 5.0 |
Calcium/metabolism | 6 | 0.0 |
Protein Structure, Secondary | 5 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Hemodynamic Processes | 3 | 1.0 |
Enzyme Induction | 2 | 0.0 |
Isoenzymes/genetics | 2 | 0.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Antithrombins/*analysis | 3 | 33.0 |
Heparin Cofactor II/analysis | 3 | 60.0 |
Serine Proteinase Inhibitors/blood | 2 | 25.0 |
Evolution, Molecular | 2 | 0.0 |
Gluconeogenesis | 2 | 15.0 |
Protein C/*chemistry/genetics/metabolism | 2 | 100.0 |
Preoperative Care | 2 | 1.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
Blood Proteins/*analysis | 4 | 2.0 |
Peptide Fragments/analysis | 4 | 1.0 |
Carcinoma, Non-Small-Cell Lung/*drug therapy | 2 | 7.0 |
Lung Neoplasms/*drug therapy | 2 | 4.0 |
Multivariate Analysis | 3 | 0.0 |
Exons | 5 | 0.0 |
Genomic Library | 2 | 0.0 |
Introns | 2 | 0.0 |
Placenta/enzymology | 2 | 2.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Protein S Deficiency/*genetics | 2 | 12.0 |
Venous Thrombosis/*blood/epidemiology | 2 | 100.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Diagnosis, Differential | 5 | 0.0 |
Immunophenotyping | 6 | 0.0 |
Protein C/*pharmacology | 2 | 3.0 |
Thrombin/*metabolism | 7 | 8.0 |
Heterozygote | 9 | 0.0 |
Protein S Deficiency/complications/epidemiology/genetics | 2 | 100.0 |
Necrosis | 2 | 0.0 |
Apoptosis | 2 | 0.0 |
Blood Coagulation/*physiology | 5 | 4.0 |
Papio | 2 | 1.0 |
Recombinant Proteins/therapeutic use | 3 | 0.0 |
Birth Weight | 2 | 1.0 |
Gestational Age | 5 | 0.0 |
Infant, Premature | 3 | 2.0 |
*Biosensing Techniques | 3 | 11.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Fluorescent Dyes | 4 | 1.0 |
Hydrolysis | 8 | 1.0 |
Phospholipase D/metabolism | 2 | 7.0 |
Protein Kinase C/metabolism | 4 | 0.0 |
DNA, Neoplasm/analysis | 4 | 0.0 |
Antibodies, Antiphospholipid/*blood | 2 | 9.0 |
Bile/metabolism | 2 | 8.0 |
Antibodies/immunology | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
Mice, Nude | 2 | 0.0 |
France | 3 | 1.0 |
Pulmonary Embolism/blood/*genetics | 2 | 100.0 |
Thrombophlebitis/blood/*genetics | 3 | 42.0 |
Spin Labels | 2 | 1.0 |
Chorionic Villi/*enzymology | 2 | 33.0 |
Liver/enzymology | 6 | 1.0 |
Pyruvate Carboxylase/*metabolism | 4 | 66.0 |
Crotalid Venoms | 2 | 50.0 |
Mutagenesis | 5 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Monocytes/*drug effects/metabolism | 3 | 3.0 |
Platelet Aggregation/drug effects | 4 | 1.0 |
Protein S Deficiency/diagnosis | 2 | 66.0 |
Fatty Acids/*analysis | 2 | 11.0 |
Hyperlipoproteinemia/*blood | 2 | 8.0 |
Lipids/*blood | 4 | 0.0 |
Thrombophlebitis/*blood | 3 | 33.0 |
Lipoproteins/blood | 3 | 0.0 |
Lipoproteins, HDL/blood | 3 | 1.0 |
Phosphatidylcholines/*blood | 7 | 46.0 |
Calcium/*pharmacology | 3 | 3.0 |
Bleeding Time | 2 | 1.0 |
Drug Evaluation | 2 | 0.0 |
von Willebrand Factor/metabolism | 3 | 1.0 |
Cell Separation | 2 | 0.0 |
Platelet Function Tests | 2 | 4.0 |
Lod Score | 2 | 0.0 |
Anticoagulants/*metabolism | 2 | 6.0 |
Catalysis | 2 | 0.0 |
Cell Count | 4 | 0.0 |
Protein C/antagonists & inhibitors/*metabolism | 3 | 33.0 |
Brain/enzymology | 2 | 1.0 |
Indians, North American/*genetics | 2 | 2.0 |
Pyruvate Carboxylase Deficiency Disease/*genetics | 2 | 100.0 |
Blood Coagulation Factors/*metabolism | 2 | 2.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Protein C/drug effects/*metabolism | 2 | 50.0 |
Fibroblasts/metabolism | 4 | 0.0 |
Phosphatidylinositols/metabolism | 2 | 1.0 |
Thrombomodulin/*genetics | 2 | 28.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 3 | 0.0 |
Biotin/*deficiency | 2 | 100.0 |
Consanguinity | 3 | 0.0 |
Fibroblasts/enzymology | 5 | 2.0 |
Lymphocytes/enzymology | 2 | 2.0 |
DNA/genetics | 6 | 0.0 |
Factor V/analysis/genetics | 2 | 22.0 |
Thrombophlebitis/etiology | 2 | 20.0 |
Warfarin/therapeutic use | 6 | 20.0 |
Rats, Sprague-Dawley | 8 | 0.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
Blood Transfusion | 2 | 1.0 |
Kidney Function Tests | 2 | 1.0 |
Liver Function Tests | 2 | 1.0 |
Postoperative Complications | 2 | 1.0 |
Linear Models | 2 | 0.0 |
Pregnancy/*blood | 2 | 1.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
Serine Endopeptidases/genetics/*metabolism | 2 | 9.0 |
Protein C Deficiency | 18 | 52.0 |
Plasmodium falciparum/*drug effects/growth & development | 2 | 50.0 |
*Gluconeogenesis | 2 | 28.0 |
Liver/*metabolism | 5 | 1.0 |
Phosphoenolpyruvate Carboxykinase (GTP)/metabolism | 2 | 40.0 |
Pyruvate Carboxylase/metabolism | 3 | 50.0 |
Calcium/metabolism/pharmacology | 2 | 6.0 |
Protein C/genetics/*metabolism | 3 | 33.0 |
Double-Blind Method | 6 | 0.0 |
Microscopy, Electron | 7 | 0.0 |
Administration, Topical | 2 | 1.0 |
Glucocorticoids/*pharmacology | 2 | 1.0 |
*Oncogenes | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Liver Transplantation/*physiology | 2 | 10.0 |
Factor Xa/metabolism | 2 | 3.0 |
Umbilical Veins | 2 | 0.0 |
Cerebral Cortex/*physiology | 2 | 4.0 |
Image Processing, Computer-Assisted/*instrumentation | 3 | 27.0 |
Cholesterol Esters/*metabolism | 3 | 3.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Genetic Vectors | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Factor VII/analysis | 3 | 10.0 |
*Protein C Deficiency | 31 | 65.0 |
Prothrombin Time | 9 | 8.0 |
Liver/*enzymology | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 2 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Plasma | 3 | 4.0 |
*Tomography, Emission-Computed | 2 | 4.0 |
Culture Media | 5 | 0.0 |
Liposomes | 4 | 1.0 |
Phosphatidylcholines/pharmacology | 2 | 10.0 |
Genetic Markers | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 3 | 0.0 |
Placenta/*metabolism | 2 | 1.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Protein C/*genetics/metabolism | 2 | 22.0 |
Choline-Phosphate Cytidylyltransferase | 10 | 83.0 |
Drug Interactions | 3 | 0.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Protein S/*physiology | 3 | 33.0 |
Chickens | 3 | 0.0 |
Cell Survival | 2 | 0.0 |
Electromyography | 2 | 1.0 |
Antibody Specificity | 6 | 0.0 |
Factor VIII/metabolism | 4 | 4.0 |
Kidney | 4 | 1.0 |
Protein Engineering | 2 | 2.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
Nucleotidyltransferases/metabolism | 6 | 60.0 |
Phosphatidylcholines/biosynthesis | 2 | 40.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Multiple Myeloma/*blood | 2 | 8.0 |
Paraproteinemias/*blood | 2 | 25.0 |
Plasma Cells/*pathology | 2 | 10.0 |
Choline Kinase/metabolism | 2 | 66.0 |
Phospholipids/*biosynthesis | 2 | 28.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 3 | 4.0 |
Sex Factors | 5 | 0.0 |
Smoking/epidemiology | 2 | 3.0 |
Thailand/epidemiology | 2 | 3.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Hematopoietic Stem Cell Transplantation/*adverse effects | 2 | 5.0 |
Calcium/*physiology | 2 | 1.0 |
Protein C/chemistry/genetics/*metabolism | 5 | 71.0 |
Endothelium, Corneal/*pathology | 2 | 40.0 |
HLA-DR Antigens/*genetics | 2 | 0.0 |
Histocompatibility Testing | 3 | 0.0 |
Biotin/*metabolism | 2 | 28.0 |
Comorbidity | 2 | 0.0 |
Antibodies, Anticardiolipin/*immunology | 2 | 40.0 |
Blood Coagulation/physiology | 2 | 3.0 |
*Protein S Deficiency | 2 | 100.0 |
Plasminogen Inactivators/blood | 5 | 19.0 |
Magnetic Resonance Spectroscopy | 4 | 0.0 |
Proteins/*metabolism | 3 | 0.0 |
Blood Coagulation Disorders/*blood | 2 | 33.0 |
Apoptosis/drug effects | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Autoantibodies/*blood | 4 | 1.0 |
Factor Va/metabolism | 2 | 6.0 |
Copper/*metabolism | 2 | 2.0 |
Carboxylic Acids/blood | 2 | 100.0 |
Disease Susceptibility | 5 | 0.0 |
Thrombophlebitis/*genetics | 2 | 12.0 |
Anemia, Sickle Cell/*blood/genetics | 2 | 50.0 |
Homozygote | 5 | 0.0 |
Software | 2 | 0.0 |
Absorption | 2 | 1.0 |
Leukocytes, Mononuclear/cytology/immunology | 2 | 4.0 |
Anticoagulants/pharmacology | 3 | 4.0 |
Factor VIII/antagonists & inhibitors | 2 | 50.0 |
Fluorescence | 3 | 1.0 |
Liposomes/*metabolism | 4 | 21.0 |
Protein C/*chemistry/genetics/*metabolism | 4 | 80.0 |
Recombinant Proteins | 2 | 0.0 |
Chromatography, Thin Layer | 3 | 1.0 |
Bronchoalveolar Lavage Fluid/chemistry | 3 | 4.0 |
*Carbon-Nitrogen Ligases | 2 | 13.0 |
Consensus Sequence | 2 | 0.0 |
*Light | 2 | 5.0 |
Radiation-Sensitizing Agents | 2 | 28.0 |
Postoperative Complications/epidemiology | 2 | 4.0 |
Pregnancy Complications, Hematologic/epidemiology | 3 | 75.0 |
Lipoproteins/metabolism | 2 | 1.0 |
Cholesterol/blood | 5 | 0.0 |
Triglycerides/blood | 4 | 0.0 |
Erythrocytes/metabolism | 2 | 1.0 |
Infant Food/*analysis | 2 | 18.0 |
Phosphatidylcholines/chemistry | 3 | 15.0 |
*Visual Acuity | 2 | 12.0 |
Hematocrit | 3 | 0.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Phylogeny | 3 | 0.0 |
*Proprotein Convertases | 2 | 13.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Hemostasis/*physiology | 7 | 12.0 |
Fibrinogen/*analysis | 3 | 6.0 |
Aging/*metabolism | 2 | 0.0 |
Fetus | 2 | 0.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Disseminated Intravascular Coagulation/blood | 3 | 15.0 |
Thrombosis/*blood | 2 | 7.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Liver/metabolism/*pathology | 2 | 10.0 |
Glycoproteins/*blood | 7 | 9.0 |
Endothelium, Vascular/*metabolism | 3 | 1.0 |
Membrane Lipids/metabolism | 4 | 8.0 |
Receptors, Cell Surface/*metabolism | 4 | 0.0 |
Thromboembolism/genetics | 2 | 28.0 |
Antithrombin III Deficiency | 6 | 42.0 |
Phosphates/metabolism | 3 | 3.0 |
Phosphatidic Acids/metabolism | 4 | 22.0 |
*Signal Transduction | 6 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 5 | 0.0 |
Fibrinolysis/drug effects | 3 | 7.0 |
DNA/*genetics | 2 | 0.0 |
*Heterozygote | 2 | 0.0 |
*Homozygote | 2 | 1.0 |
*Variation (Genetics) | 2 | 0.0 |
Proliferating Cell Nuclear Antigen/*analysis | 2 | 1.0 |
Radioligand Assay | 2 | 0.0 |
Plasma Cells/*immunology | 2 | 7.0 |
Epitopes/immunology | 5 | 0.0 |
Immunoblotting | 7 | 0.0 |
Pyruvate Carboxylase/*genetics | 2 | 100.0 |
*Blood Donors | 2 | 1.0 |
Colonic Neoplasms/*pathology | 2 | 2.0 |
Diglycerides/*metabolism | 4 | 22.0 |
Protein Kinase C/*metabolism | 2 | 0.0 |
Blood Cell Count | 2 | 0.0 |
*Blood Component Removal | 2 | 6.0 |
Cyclophosphamide/administration & dosage | 3 | 1.0 |
Doxorubicin/administration & dosage | 3 | 1.0 |
*Plasma Cells | 2 | 100.0 |
*Photochemotherapy | 2 | 4.0 |
Fibroblasts/cytology/metabolism | 2 | 1.0 |
Electron Spin Resonance Spectroscopy | 2 | 0.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Microcomputers | 3 | 30.0 |
*Heat | 2 | 1.0 |
Fetus/metabolism | 2 | 1.0 |
Maternal-Fetal Exchange | 3 | 2.0 |
Chemistry, Physical | 2 | 1.0 |
Acylation | 3 | 4.0 |
Linoleic Acids/blood | 3 | 33.0 |
Chimeric Proteins/chemistry/metabolism | 2 | 3.0 |
Protein C/chemistry/*metabolism | 2 | 25.0 |
Restriction Mapping | 3 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Protein C/*chemistry | 2 | 22.0 |
*Aneuploidy | 2 | 2.0 |
Heparin/pharmacology | 4 | 1.0 |
Phospholipids/*blood | 8 | 24.0 |
Sphingomyelins/blood | 2 | 40.0 |
1-Carboxyglutamic Acid/chemistry/*metabolism | 2 | 100.0 |
Phospholipases A/*metabolism | 3 | 6.0 |
Nephrotic Syndrome/*blood | 2 | 13.0 |
Chromatography, Affinity | 4 | 0.0 |
Anticoagulants | 2 | 10.0 |
Serum Albumin/analysis | 3 | 1.0 |
Lupus Coagulation Inhibitor/*blood | 2 | 15.0 |
Disease Susceptibility/epidemiology | 2 | 33.0 |
Genes, Dominant | 2 | 0.0 |
Linoleic Acid | 2 | 7.0 |
Membrane Lipids/*blood | 2 | 20.0 |
Quality Control | 2 | 1.0 |
Cisplatin/administration & dosage | 2 | 0.0 |
Calcium/*metabolism/pharmacology | 2 | 7.0 |
Fibrin/analysis | 2 | 6.0 |
Fibrinogen/analysis | 6 | 3.0 |
Gene Library | 2 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
Endothelium, Vascular/cytology | 2 | 0.0 |
Thrombin/*pharmacology | 2 | 1.0 |
Amino Acid Chloromethyl Ketones/pharmacology | 2 | 1.0 |
Endothelium, Vascular/*physiology | 2 | 1.0 |
P-Glycoprotein | 2 | 4.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Nucleotidyltransferases/*antagonists & inhibitors | 2 | 100.0 |
Calcium/physiology | 2 | 0.0 |
Liver/embryology/*metabolism | 2 | 18.0 |
Energy Metabolism | 2 | 1.0 |
Lymphocytes/drug effects/*metabolism | 2 | 8.0 |
Blood Donors | 3 | 1.0 |
Plasminogen/*analysis | 2 | 22.0 |
1-Carboxyglutamic Acid/*chemistry | 3 | 27.0 |
Amino Acids | 2 | 6.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Half-Life | 2 | 0.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Genistein | 2 | 2.0 |
Isoflavones/pharmacology | 2 | 3.0 |
*Protein Kinase Inhibitors | 2 | 3.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Anticoagulants/administration & dosage | 2 | 14.0 |
Infusions, Intravenous | 2 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
*Blood Platelets | 2 | 9.0 |
*Blood Preservation | 2 | 3.0 |
Centrifugation | 2 | 2.0 |
Leukocyte Count | 5 | 0.0 |
*Leukocytes | 2 | 10.0 |
Mechanoreceptors/*physiology | 4 | 40.0 |
Skin/*innervation | 2 | 9.0 |
Protein S Deficiency | 2 | 28.0 |
Antiplasmin/analysis | 2 | 5.0 |
Fibrinopeptide A/analysis | 2 | 4.0 |
Plasmin/analysis | 2 | 4.0 |
Plasminogen/analysis | 2 | 11.0 |
Diacylglycerol Kinase | 2 | 50.0 |
Diacylglycerol Cholinephosphotransferase/*metabolism | 2 | 100.0 |
Calcium/*blood | 2 | 2.0 |
Solubility | 5 | 0.0 |
Fatty Acids/blood | 3 | 6.0 |
Protein S/*blood/immunology | 2 | 100.0 |
X-Ray Diffraction | 2 | 2.0 |
Thrombosis/blood/*genetics | 2 | 28.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Combined Modality Therapy | 2 | 0.0 |
Fatty Acids, Unsaturated/*metabolism | 3 | 14.0 |
Probability | 2 | 0.0 |
Renal Dialysis | 3 | 0.0 |
Variation (Genetics) | 2 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Prenatal Diagnosis | 3 | 1.0 |
Antigens, CD/analysis | 2 | 0.0 |
Cold | 2 | 1.0 |
Drug Therapy, Combination | 2 | 0.0 |
Pyrrolidonecarboxylic Acid/analogs & derivatives | 2 | 8.0 |
Blood Coagulation Disorders/*drug therapy/genetics | 2 | 100.0 |
Molecular Structure | 2 | 0.0 |
Chromogenic Compounds/metabolism | 2 | 25.0 |
Fibrinolysis/*physiology | 3 | 3.0 |
Mice, Inbred CBA | 2 | 0.0 |
Protein S | 18 | 34.0 |
Adsorption | 2 | 1.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Thromboembolism/*blood | 2 | 25.0 |
*Catheters, Indwelling | 2 | 50.0 |
Danazol/administration & dosage/*therapeutic use | 2 | 100.0 |
Glycoproteins/*analysis | 5 | 7.0 |
Thrombosis/etiology | 3 | 4.0 |
Receptors, Thrombin | 7 | 14.0 |
Edetic Acid/pharmacology | 3 | 1.0 |
Immunoelectrophoresis | 4 | 1.0 |
Glycoproteins/deficiency | 2 | 66.0 |
Glycoproteins/*metabolism | 7 | 3.0 |
Thrombin/*analysis | 2 | 13.0 |
Lupus Coagulation Inhibitor | 5 | 41.0 |
Plasminogen Inactivators/*blood | 2 | 10.0 |
Tissue Plasminogen Activator/*blood | 2 | 6.0 |
Rats, Inbred Strains | 3 | 0.0 |
Kidney Failure, Chronic/blood/therapy | 2 | 6.0 |
Antigens/analysis | 3 | 2.0 |
Protein C/immunology/*metabolism | 2 | 50.0 |
Septicemia/complications | 2 | 33.0 |
Chromatography, Gel | 2 | 0.0 |
Liver Cirrhosis/*blood | 2 | 5.0 |
Amides/metabolism | 3 | 20.0 |
*Carbon-Carbon Ligases | 3 | 23.0 |
Biological Markers/analysis | 2 | 0.0 |
Cross Reactions/immunology | 2 | 4.0 |
Antibodies, Monoclonal/*immunology | 2 | 0.0 |
Amniotic Fluid/*analysis | 3 | 4.0 |
Fetal Organ Maturity | 2 | 22.0 |
Phospholipids/*analysis | 4 | 26.0 |
Lymphocyte Activation | 2 | 0.0 |
Protein C/*analysis/immunology/physiology | 2 | 100.0 |
Liver Cirrhosis/blood | 3 | 7.0 |
Fibrinopeptide A/metabolism | 2 | 8.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Anticoagulants/*administration & dosage/therapeutic use | 2 | 33.0 |
Warfarin/pharmacology | 2 | 13.0 |
Protein Kinases/metabolism | 2 | 0.0 |
China/ethnology | 2 | 1.0 |
Placebos | 3 | 1.0 |
Infant, Premature/*blood | 2 | 6.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Immunoglobulin G/isolation & purification | 2 | 15.0 |
Plasminogen Inactivators | 2 | 13.0 |
C-Reactive Protein/*metabolism | 2 | 0.0 |
Choline/*analogs & derivatives | 2 | 33.0 |
Chromogenic Compounds | 2 | 9.0 |
Amniocentesis | 2 | 2.0 |
Methods | 2 | 0.0 |
Phospholipase C/pharmacology | 2 | 5.0 |
Aldosterone/*blood | 2 | 4.0 |
Hydrocortisone/*blood | 2 | 1.0 |
Renin/*blood | 4 | 4.0 |
Immunodiffusion | 3 | 1.0 |
Protein C/*blood | 3 | 100.0 |
Inflammation | 4 | 1.0 |
Chemistry | 2 | 0.0 |
Sudan | 2 | 11.0 |
Cholecystectomy | 2 | 11.0 |
Blood Coagulation Tests/methods | 2 | 20.0 |
Reagent Kits, Diagnostic | 2 | 1.0 |
*Pyruvate Carboxylase Deficiency Disease | 5 | 100.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Protein C | 10 | 50.0 |
Lithium/therapeutic use | 2 | 16.0 |
Methylation | 3 | 0.0 |
Arachidonic Acid | 2 | 3.0 |
Blood Glucose/analysis | 2 | 0.0 |
Fibroblasts/*enzymology | 2 | 5.0 |
Genetic Complementation Test | 2 | 0.0 |
Lipoprotein Lipase/*metabolism | 3 | 1.0 |
Ethanol/*adverse effects | 3 | 12.0 |
Prostatectomy | 2 | 2.0 |
Binding Sites, Antibody | 2 | 0.0 |
Serum Albumin/pharmacology | 2 | 5.0 |
Argipressin/*blood | 2 | 0.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Chlormethiazole/administration & dosage | 2 | 100.0 |
Clinical Trials | 2 | 0.0 |
Hydrocortisone/*analysis | 2 | 33.0 |
Norepinephrine/*blood | 2 | 3.0 |
Substance Withdrawal Syndrome/*drug therapy/metabolism | 2 | 100.0 |
Timolol/*therapeutic use | 2 | 100.0 |
Lupus Coagulation Inhibitor/blood | 2 | 15.0 |
Electric Stimulation | 2 | 0.0 |
Evoked Potentials | 2 | 3.0 |
Nerve Fibers, Myelinated/physiology | 2 | 40.0 |
Physical Stimulation | 2 | 4.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Brain/pathology | 2 | 0.0 |
Methylmalonyl-CoA Decarboxylase | 2 | 10.0 |
Median Nerve/physiology | 2 | 11.0 |
Sex Distribution | 2 | 0.0 |
